TELA Stock Overview
A commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TELA Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.90 |
| 52 Week High | US$7.84 |
| 52 Week Low | US$2.30 |
| Beta | 0.97 |
| 11 Month Change | 15.54% |
| 3 Month Change | 0.69% |
| 1 Year Change | -40.21% |
| 33 Year Change | -77.13% |
| 5 Year Change | -75.79% |
| Change since IPO | -78.28% |
Recent News & Updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely
Nov 09
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%
Aug 19Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely
Nov 09Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%
Aug 19Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?
Jul 03Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Shareholder Returns
| TELA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.2% | -0.8% | -1.2% |
| 1Y | -40.2% | 20.9% | 30.4% |
Return vs Industry: TELA underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: TELA underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| TELA volatility | |
|---|---|
| TELA Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TELA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TELA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 227 | Antony Koblish | www.telabio.com |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.
TELA Bio, Inc. Fundamentals Summary
| TELA fundamental statistics | |
|---|---|
| Market cap | US$114.62m |
| Earnings (TTM) | -US$41.52m |
| Revenue (TTM) | US$68.65m |
1.7x
P/S Ratio-2.8x
P/E RatioIs TELA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELA income statement (TTM) | |
|---|---|
| Revenue | US$68.65m |
| Cost of Revenue | US$21.38m |
| Gross Profit | US$47.27m |
| Other Expenses | US$88.79m |
| Earnings | -US$41.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 68.86% |
| Net Profit Margin | -60.49% |
| Debt/Equity Ratio | -653.2% |
How did TELA perform over the long term?
See historical performance and comparison